The Study of Biomarkers inSmokers Infected with Covid-19 in Basra, Iraq
Main Article Content
Abstract
Background: The COVID-19 pandemic has heightened awareness of infectious illnesses and their links to host variables and underlying disorders. Objectives: In this review, we look at current research on a possible link between smoking and COVID-19 and study the biomarker changes in patients. Material and Methods: A case-control study included 45 smoker’s patients with COVID-19 and 50 healthy subjects as a control group who visited Al-Basra Teaching Hospital and Allmwanei Hospital in Al-Basra province between October 2021 and February 2022. The age average for the study population was (25-80) years. Serum and blood levels of human CBC, ESR, CRP, Ferritin, D-Dimer, IL 6, Albumin, FBS, HbA1c, Troponin, Cholesterol, Triglyceride, HDL, LDL, VLDL, Creatinine, Urea, Uric acid and GFR were measured. Results: The results show all biomarkers tend to have high sensitivity and specificity for smoker COVID patients based on the ROC curve analysis: Lymphocyte, CRP, Ferritin, D-Dimer, IL 6, Albumin, FBS, HDL, Creatinine, Urea, and GFR. These biomarkers might be helpful in determining the kind and severity of COVID-19 in smokers. Although the data is limited to a total number of patients. Conclusion: Studying patient alterations and vital signs led to the conclusion that smoking and COVID-19 are related. It was also verified that all vital indicators had strong sensitivity and specificity for smoking COVID patients.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Pal M, Berhanu G, Desalegn C, Kandi V. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus. 2020;12(3).
II. Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infect Genet Evol. 2020;83:104327.
III. Patanavanich R, Glantz SA. Smoking is associated with COVID-19 progression: a meta-analysis. Nicotine Tob Res. 2020;22(9):1653–6.
IV. Yang J, Zheng YA, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5.
V. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N, et al. The impact of COPD and smoking history on the severity of COVID‐19: A systemic review and meta‐analysis. J Med Virol. 2020;92(10):1915–21.
VI. Pedersen SF, Ho Y-C. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130(5):2202–5.
VII. Organization WH. WHO report on the global tobacco epidemic, 2021: addressing new and emerging products. World Health Organization; 2021.
VIII. West R. Review of" Smoking, vaping and hospitalization for COVID-19.
IX. Gibson PG, Qin L, Puah SH. COVID‐19 acute respiratory distress syndrome (ARDS): clinical features and differences from typical pre‐COVID‐19 ARDS. Med J Aust. 2020;213(2):54–6.
X. Darif D, Hammi I, Kihel A, Saik IEI, Guessous F, Akarid K. The pro-inflammatory cytokines in COVID-19 pathogenesis: What goes wrong? Microb Pathog. 2021;153:104799.
XI. Umnuaypornlert A, Kanchanasurakit S, Lucero-Prisno DEIII, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: a systematic review and meta-analysis. Tob Induc Dis. 2021;19.
XII. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID‐19 severity: A systematic review and meta‐analysis. J Med Virol. 2021;93(2):1045–56.
XIII. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. bmj. 2020;369.
XIV. Yang W, Kandula S, Huynh M, Greene SK, Van Wye G, Li W, et al. Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis. Lancet Infect Dis. 2021;21(2):203–12.
XV. Scholz JR, Lopes MACQ, Saraiva JFK, Colombo FC. COVID-19, renin-angiotensin system, angiotensin-converting enzyme 2, and nicotine: what is the interrelation? Arq Bras Cardiol. 2020;115:708–11.
XVI. Huang J, Cheng A, Kumar R, Fang Y, Chen G, Zhu Y, et al. Hypoalbuminemia predicts the outcome of COVID‐19 independent of age and co‐morbidity. J Med Virol. 2020;92(10):2152–8.
XVII. Chen C, Zhang Y, Zhao X, Tao M, Yan W, Fu Y. Hypoalbuminemia–An indicator of the severity and prognosis of COVID-19 patients: a multicentre retrospective analysis. Infect Drug Resist. 2021;3699–710.
XVIII. Sleep D, Cameron J, Evans LR. Albumin as a versatile platform for drug half-life extension. Biochim Biophys Acta (BBA)-General Subj. 2013;1830(12):5526–34.
XIX. Mintz Y, Arezzo A, Boni L, Baldari L, Cassinotti E, Brodie R, et al. The risk of COVID-19 transmission by laparoscopic smoke may be lower than for laparotomy: a narrative review. Surg Endosc. 2020;34:3298–305.
XX. Cetin Kargin N. The effect of smoking on COVID‐19–linked biomarkers in hospitalized patients with COVID‐19. J Clin Lab Anal. 2021;35(10):e23983.
XXI. Luis Abreu J, Hibberd J. Two Mechanism: Artemisia annua Targeting Ferritin & Ivermectin Stopping Viral Replication. Rev Daena (International J Good Conscienc. 2020;15(3).
XXII. Farsalinos K, Niaura R, Le Houezec J, Barbouni A, Tsatsakis A, Kouretas D, et al. Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system. Toxicol reports. 2020;7:658.
XXIII. Korzeniowska A, Ręka G, Bilska M, Piecewicz-Szczęsna H. The smoker’s paradox during the COVID-19 pandemic? The influence of smoking and vaping on the incidence and course of SARS-CoV-2 virus infection as well as possibility of using nicotine in the treatment of COVID-19-Review of the literature. Epidemiol Rev Epidemiol. 2021;75(1).
XXIV. Lagoumintzis G, Chasapis CT, Alexandris N, Kouretas D, Tzartos S, Eliopoulos E, et al. Nicotinic cholinergic system and COVID-19: In silico identification of interactions between α7 nicotinic acetylcholine receptor and the cryptic epitopes of SARS-Co-V and SARS-CoV-2 Spike glycoproteins. Food Chem Toxicol. 2021;149:112009.